Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.

Blood
Giovanni PalladiniGiampaolo Merlini

Abstract

The management of light chain (AL) amyloidosis has improved in recent years thanks to accurate biomarker-based staging systems and response criteria and availability of novel effective therapies. However, previous studies have focused on newly diagnosed patients, and little is known on relapsed patients, despite the fact that trials of new agents are often performed in this setting. In the present study, we report the outcome of 259 patients who responded to up-front therapy. Ninety-two patients (35%) needed second-line therapy after a median of 49 months. Cardiac and renal progression were observed in 22% and 12% of patients who received second-line therapy, respectively. Complete response after up-front treatment and frontline therapy with combined bortezomib, melphalan, and dexamethasone independently prolonged time to second-line therapy. Median survival of relapsing patients was 59 months. Patients who had a "high-risk dFLC progression," which we defined as a difference between involved and uninvolved free light chains (dFLC) of >20 mg/L, a level >20% of baseline value, and a >50% increase from the value reached at best response, had a shorter survival after initiation of second-line therapy on univariate, but not on multi...Continue Reading

References

Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angela DispenzieriAllan S Jaffe
Oct 24, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giovanni PalladiniGiampaolo Merlini
May 15, 2013·Blood·Giampaolo MerliniGiovanni Palladini
Oct 3, 2013·Journal of Proteome Research·Francesca BrambillaPierluigi Mauri
Jan 25, 2014·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Tilmann BochtlerStefan O Schönland
Oct 11, 2014·British Journal of Haematology·Ashutosh D WechalekarUNKNOWN BCSH Committee
Feb 1, 2015·Blood·Carlos Fernández de LarreaGiampaolo Merlini
Mar 18, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tilmann BochtlerStefan O Schönland
Aug 1, 2015·Blood·M Teresa Cibeira, Joan Bladé
Feb 5, 2016·Clinical Chemistry and Laboratory Medicine : CCLM·David R BarnidgeDavid L Murray
Apr 8, 2016·Blood·Giovanni Palladini, Giampaolo Merlini
Apr 15, 2017·Blood·Donna E Reece
Apr 15, 2017·Blood·Angela Dispenzieri
Apr 25, 2017·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Francesca RussoGiampaolo Merlini
Apr 26, 2017·American Journal of Hematology·Paolo MilaniAngela Dispenzieri
Sep 1, 2017·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Paolo MilaniAngela Dispenzieri

❮ Previous
Next ❯

Citations

Feb 14, 2018·Blood·Angela Dispenzieri
May 24, 2019·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Lisa Xingguang LeeRaymond L Comenzo
Jun 30, 2019·American Journal of Hematology·Surbhi SidanaMorie A Gertz
Feb 7, 2020·Blood Advances·Alfred ChungMichaela Liedtke
Feb 29, 2020·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Ramón LecumberriM Teresa Cibeira
Aug 1, 2020·Expert Opinion on Emerging Drugs·Rajshekhar Chakraborty, Suzanne Lentzsch
Dec 21, 2018·Aging·Maria GavriatopoulouMeletios Athanasios Dimopoulos
Oct 27, 2018·Nature Reviews. Disease Primers·Giampaolo MerliniMorie A Gertz
Sep 20, 2018·F1000Research·Talha BadarParameswaran Hari
Apr 12, 2019·Proceedings of the National Academy of Sciences of the United States of America·Gareth J MorganJeffery W Kelly
Jul 30, 2020·Expert Review of Hematology·Marco BassetGiampaolo Merlini
Jan 24, 2019·Blood Advances·Giovanni Palladini, Giampaolo Merlini
Dec 5, 2020·Hematology·Giovanni PalladiniGiampaolo Merlini
Dec 4, 2020·Blood·Giovanni PalladiniGiampaolo Merlini
Apr 15, 2019·Néphrologie & thérapeutique·Arnaud Jaccard, Frank Bridoux
Jun 6, 2021·Mayo Clinic Proceedings·Giovanni Palladini, Giampaolo Merlini
Aug 4, 2021·Critical Reviews in Oncology/hematology·Hamza HassanHamza Hashmi
May 1, 2020·Acta Haematologica·Paolo Milani, Giovanni Palladini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Amyloidosis

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Discover the latest research on cardiac amyloidosis here.